A Vaccine for Lymphatic Filariasis, LFGuard™
淋巴丝虫病疫苗 LFGuard™
基本信息
- 批准号:10200657
- 负责人:
- 金额:$ 100万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-01 至 2023-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAffectAgonistAnimal ModelAntigensBiologicalBiological AssayBrugia malayiCanis familiarisCellsChronicClinicalClinical ResearchClinical TrialsContractsCountryCoupledCulicidaeDevelopmentDiseaseEngineeringFermentationFilaria bancroftiFilarial ElephantiasesFutureGrantHelminthsHumanImmunityIndividualInfectionInfection ControlInterruptionLeadLymphaticLymphedemaMacaca mulattaMusNatureParasitesPathologyPharmaceutical PreparationsPharmacotherapyPhasePopulations at RiskPreventative vaccinationPreventive vaccineProceduresProcessProductionProphylactic treatmentProteinsRecombinant Fusion ProteinsRecordsResearchResourcesRiskRodentRodent ModelRunningSafetySeedsSmall Business Innovation Research GrantSterilityTLR4 geneTechnologyTestingTimeToxicologyVaccinationVaccinesVial deviceWorkWritingaluminum sulfatedesigndisability-adjusted life yearsdisease transmissionefficacy testinggerbil/jirdglobal healthin vivomeetingsneglectneglected tropical diseasesnonhuman primatephysically handicappedpre-clinicalpreclinical developmentprogramsprophylacticstability testingtransmission processvaccine candidate
项目摘要
PROJECT SUMMARY
Lymphatic filariasis (LF) is a mosquito-transmitted, neglected tropical disease (NTD) affecting over 120 million
people living in 72 countries. Current control strategies for LF infection which rely on annual mass drug
administration (MDA) to the “at-risk” populations has failed to interrupt disease transmission partly due to chronic
reinfection. There is no licensed prophylactic vaccine currently available for the LF, and of those tested over the
last 2 decades have advanced beyond rodent testing. This is partly because of poor protection, but also due to
lack of resources to advance the technology given its truly neglected nature.
We have developed and established the first successful multivalent recombinant fusion protein (Bm-HAXT) for
the prophylaxis of LF called LFGuard™. This vaccine is comprised of a protein antigen, Bm-HAXT, formulated
with the TLR4 agonist GLA-on-Alum. When formulated, our vaccine is highly stable and provides nearly sterile
immunity in rodents (>95%) and significant protection in non-human primates (70%). To date LFGuard™ has
been extensively tested and confirmed for its prophylactic potential and safety in different animal models such
as mice (n=980), Mongolian gerbils (jirds) (n=220), and rhesus macaques (n=60). In addition to treatment of LF,
LFGuard™ has also shown significant promise in dogs as a vaccine for heartworms.
This SBIR Phase 2 proposal will allow us to move LFGuard™ into pre-clinical development including GMP
manufacture, vialing, and stability and efficacy testing. A clinical study and a supporting toxicology study will be
designed, and stability will be confirmed through both short- and long-term stability programs. Finally, we will
conduct a pre-IND meeting with the FDA prior to execution of the toxicology study. When these studies are
complete, this important antigen will be poised to enter the first human clinical trials for the first ever lymphatic
filariasis vaccine. We propose the following aims for this SBIR Phase 2 grant: (1) Manufacture of BmHAXT under
cGMPs (2) Perform pre-clinical IND-enabling studies.
项目总结
淋巴丝虫病(LF)是一种通过蚊子传播的被忽视的热带疾病(NTD),影响超过1.2亿人
生活在72个国家的人们。依赖年度集体用药的LF感染控制策略
对高危人群的管理(MDA)未能阻断疾病的传播,部分原因是慢性
再感染。目前还没有获得许可的预防性疫苗可供LF使用,并且在
在过去的20年里,啮齿动物测试已经取得了进步。这部分是因为保护不力,但也是因为
鉴于其真正被忽视的性质,缺乏推动这项技术的资源。
我们开发并建立了第一个成功的多价重组融合蛋白(BM-HAXT),用于
LF的预防称为LFGuard™。这种疫苗是由一种蛋白质抗原BM-HAXT组成的
使用TLR4激动剂GLA-on-Alum。在配制疫苗时,我们的疫苗高度稳定,几乎无菌
啮齿类动物的免疫力(95%)和非人灵长类动物的显著保护(70%)。迄今为止,LFGuard™已经
在不同的动物模型上进行了广泛的预防潜力和安全性的测试和确认
作为小鼠(n=980)、蒙古沙鼠(n=220)和恒河猴(n=60)。除治疗LF外,
LFGuard™在狗身上也显示出作为心虫疫苗的重大前景。
这份SBIR第二阶段提案将允许我们将LFGuard™转移到临床前开发中,包括GMP
制造、装瓶、稳定性和药效测试。一项临床研究和一项辅助毒理学研究将
设计,稳定性将通过短期和长期稳定计划得到确认。最后,我们会
在执行毒理学研究之前,与FDA召开IND前会议。当这些研究是
完成后,这种重要的抗原将进入有史以来第一次淋巴系统的人类临床试验。
丝虫病疫苗。我们为SBIR第二阶段赠款提出了以下目标:(1)在以下条件下制造BmHAXT
CGMP(2)进行临床前IND使能研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DARRICK Albert CARTER其他文献
DARRICK Albert CARTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DARRICK Albert CARTER', 18)}}的其他基金
Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines
带佐剂的重组候选物可用于启动/增强 COVID-19 RNA 疫苗
- 批准号:
10325834 - 财政年份:2021
- 资助金额:
$ 100万 - 项目类别:
Developing a Screen for New Adjuvants to Enhance RNA Vaccines
开发增强 RNA 疫苗的新佐剂筛选方案
- 批准号:
10189513 - 财政年份:2020
- 资助金额:
$ 100万 - 项目类别:
CruziScreen, a recombinant antigen-based screening test for Chagas disease
CruziScreen,一种基于重组抗原的恰加斯病筛查测试
- 批准号:
9407719 - 财政年份:2017
- 资助金额:
$ 100万 - 项目类别:
JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer
JOC-x:打开肿瘤紧密连接以治疗癌症的化疗结合物
- 批准号:
10020907 - 财政年份:2016
- 资助金额:
$ 100万 - 项目类别:
A recombinant protein that increases engraftment of hematopoietic stem cells
一种增加造血干细胞植入的重组蛋白
- 批准号:
9048950 - 财政年份:2016
- 资助金额:
$ 100万 - 项目类别:
Tumor Tight Junction Opener + Chemotherapy Conjugates to Treat Cancer
肿瘤紧密连接开放剂化疗结合物治疗癌症
- 批准号:
8647718 - 财政年份:2014
- 资助金额:
$ 100万 - 项目类别:
A Vaccine for Schistosomiasis, "SchistoShield"
血吸虫病疫苗“SchistoShield”
- 批准号:
10341126 - 财政年份:2013
- 资助金额:
$ 100万 - 项目类别:
A Vaccine for Schistosomiasis, "SchistoShield"
血吸虫病疫苗“SchistoShield”
- 批准号:
10011501 - 财政年份:2013
- 资助金额:
$ 100万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 100万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 100万 - 项目类别:
Studentship














{{item.name}}会员




